DNMT3A mutations occur in 15%–25% of adult AML patients and up to 36% of adults with intermediate-risk normal cytogenetic AML harbor a mutation in DNMT3A (12) and are early hits in hematopoietic stem cells (15, 16). Here, DNMT3A is linked to acute myeloid leukemia.